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Introduction 
The nuclear hormone receptor peroxisome 
proliferator-activated receptor (PPAR) γ is a 
ligand-activated transcription factor that 
regulates several biological processes such as 
adipogenesis, glucose homeostasis and cell 
growth. Several polyunsaturated fatty acids, 
the thiazolidinediones (TZDs) class of 
antidiabetic drugs and the nuclear prostanoid 
15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) 
has been identified as ligands for PPARγ (for 
review, see Na and Surh, 2003).  
PPARγ is expressed at significant levels in 
human liposarcoma and breast 
adenocarcinoma and treatment with PPARγ 
ligands reduces the growth rate and induces 
terminal differentiation of these malignant 
cells (Tontonoz et al., 1997, Mueller et al., 
1998). In the large intestine, PPARγ is 
expressed in human colonic mucosa, colon 
adenocarcinoma and cultured colon cancer 
cells (Sarraf et al., 1998). However, the exact 
role of PPARγ in colon cancers has not been 
elucidated. 
In the present study, we investigate the 
effect of ciglitazone, a PPARγ ligand on the 
mRNA and protein expression of PPARγ and 
its ability to inhibit growth and induce 
apoptosis in two colon cancer cell lines: HT-
29 and COLO 205. We found that ciglitazone 
inhibited growth and induced apoptosis in 
both cell lines. Unexpectedly, results from this 
study also showed that ciglitazone activity 
downregulated PPARγ mRNA and protein 
expression. Therefore, we suggest that the 
antitumour effects of ciglitazone may be 
independent of PPARγ. 
 
Materials and methods 
 
Chemicals  
Ciglitazone (Cayman Chemicals, USA) 
was dissolved in dimethyl sulphoxide 
(DMSO) (Sigma, USA) to obtain a 100 mM 
stock solution. Final concentration of the 
DMSO in culture medium was not more than 
0.03%.  
 
Cell culture  
HT-29 and COLO 205 were cultured in 
RPMI 1640 (Gibco BRL, USA) supplemented 
with 10% fetal bovine serum (FBS) (Gibco 
BRL) and 100 U/ml and 100 mg/ml 
Penicillin/Streptomycin solution. The cells 
were maintained in a humidified atmosphere 
in 5% CO2 at 37°C.  
 
Cytotoxicity Assay 
As an index of cytotoxicity, lactate 
dehydrogenase (LDH) leakage was measured 
using the Cytotoxicity Detection Kit (LDH) 
(Roche, Germany). Cells were seeded in 24-
well plates at a concentration of 1×105 
cells/ml in RPMI (the optimum cell number 
for this assay was determined in preliminary 
experiments) until they reached about 70% 
confluence. The growth medium was removed 
and replaced with RPMI containing 2% FBS. 
Cells were incubated with various 
concentrations of ciglitazone for 6 to 72 h. To 
determine maximum LDH release, cells were 
solubilised with a final concentration of 1% 
(w/v) Triton X-100. Spontaneous LDH release 
(low control) was determined by incubating 
the cells with medium alone. Supernatants 
were removed and centrifuged. Cell-free 
supernatants were then transferred to clean 96-
well plates. LDH activity was assayed in the 
supernatants by a reaction in which the 
tetrazolium salts, INT, was reduced to a red 
formazan salt. Absorbance was read at 490 nm 
with a microplate reader. Results were 
expressed as  % cytotoxicity [(experimental 
value-low control/high control-low control) × 
100]. Effective concentration (EC50) values 
were expressed as micromolar of ciglitazone 
concentration that causes a 50% growth 
inhibition as compared to controls.  
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RNA isolation and real-time quantitative 
polymerase chain reaction  
Total RNA was isolated from cells using the 
RNeasy™ Total RNA Kit (Qiagen, Germany) 
and first strand cDNA was synthesised using 
the Revert Aid™ H Minus First Strand cDNA 
Synthesis Kit (Fermentas, USA). Real-time 
quantitative PCR was performed in the ABI 
Prism 7000 Sequence Detection System 
(Applied Biosystems, USA) using Taqman 
probes and primers.  To prepare standard 
samples for real-time PCR, conventional RT-
PCR was performed and PCR products were 
cloned into the TOPO® vector (Invitrogen, 
USA) and transformed into E.coli competent 
cells. The recombinant plasmid was isolated 
and sent for sequencing to confirm the 
presence of PPARγ1 fragment.  The 
concentration of the plasmid was adjusted to 1 
pmol/µl and used as standard samples 
(ranging from 10-4 to 10-8 pmol copies) for 
generating a standard curve for each 
quantitative PCR experiment. The primer 
sequences for PPARγ1 gene were as follows: 
forward primer, 5’-CTT TAT GGA GCC 
CAA GTT TGA GTT-3’ and reverse primer, 
5’-GGC TTC ACA TTC AGC AAA CCT C-
3’ (129 bp). The sequences for PPARγ1 probe 
was 5’-CAC TGG AAT TAG ATG ACA 
GCG ACT TGG CA-3’. The reaction was 
initiated at 50°C for 2 min. This step was 
required for optimal AmpErase® uracyl-N-
glycosylase (UNG) enzyme activity. The 
temperature was increased to 95°C for 10 min 
to activate the AmpliTaq Gold enzyme. This 
was followed by 40 cycles at 95°C for 15 sec 
and 60°C for 1 min.  
 
Western Blotting  
Cells grown in 75 cm2-flasks were harvested  
and lysed in lysis buffer containing 50 mM 
Tris HCl, 150 mM NaCl, 1% Nonidet P-40 
(NP-40), 0.2% sodium dodecyl sulfate (SDS), 
1 mM phenylmethylsufonyl flouride (PMSF), 
2 µg/ml leupeptin, 2 µg/ml aprotinin and 1 
mM sodium orthovanadate (Na3VO4). The cell 
homogenates were collected by centrifugation 
at 12,000 rpm at 4°C, and protein 
concentrations were determined using the Bio-
Rad Protein Assay Kit (Bio-Rad, CA). One 
hundred micrograms of protein from whole 
cell lysates were electrophoresed through a 
10% SDS-polyacrylamide gel. Proteins were 
transferred onto Hybond™ ECL nitrocellulose 
membrane (Amersham Biosciences, UK). The 
membrane was blocked with 3% skim milk 
and incubated overnight at 4°C with 1:500 
goat anti-human PPARγ polyconal antibody 
(Santa Cruz Biotechnology, CA). After three 
washes with 0.1% Tween 20 in TBS, the 
membranes were incubated for 1 h at room 
temperature with peroxidase conjugated rabbit 
anti-goat IgG (1:1000 dilution) (Dako, 
Denmark). The membranes were again 
washed, and peroxidase were detected with an 
enhanced chemiluminiscence system  
(Amersham Biosciences, UK) using the 
Hyperfilm™ ECL  (Amersham Biosciences, 
UK). 
 
Detection of apoptosis 
Cells grown in 25 cm2-flasks (1×105 cells/ml) 
were treated with either ciglitazone (at EC50 
values) or DMSO (control). After a fixed 
period of incubation, adherent and floating 
cells were combined and washed twice with 
PBS containing 0.1% Tween-20. Incubation 
of cells with M30 cytoDEATH antibody was 
then performed for 60 min at room 
temperature. The cells were washed again 
twice before resuspended in PBS. Analysis 
was done using a flow cytometer (Becton 
Dickinson, USA).  
 
Calculation and statistical analysis 
The experiments were carried out in triplicates 
for three times (n=3). Data are given as mean 
± standard error mean (sem). EC50 values 
were obtained as half-maximum-effect 
concentrations from the response curves. 
Significance was determined by conducting an 
independent Student T-test, and considering 
p<0.01 to be statistically significant.    
 
Results 
 
Ciglitazone inhibits growth of colon cancer 
cells in vitro 
The cell lines were cultured in the presence of 
various concentrations of ciglitazone to 
investigate the effect of ciglitazone on cell 
growth. Figure 1 shows that ciglitazone 
markedly inhibited cell growth in HT-29 and 
COLO 205 (p<0.01). The EC50 values of 
ciglitazone at 24 h were obtained at about 20 
µM for HT-29 and about 30 µM for COLO 
205. At all exposure times, a 100 µM of 
ciglitazone concentration caused more than 
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80% cell death. A significant inhibition of 
ciglitazone was seen at concentrations of 30  
 
µM and higher, and was observed even as 
early as 6 h.  
 
Ciglitazone downregulates PPARγ mRNA 
levels in colon cancer cell lines 
TZDs are being tested in clinical trials for 
the treatment of human cancers expressing 
high levels of PPARγ because it is assumed 
that activation of PPARγ mediates their 
anticancer activity (Grommes et al., 2004). In 
an effort to determine whether ligand 
treatment increases PPARγ transcriptional 
activity, we cultured 2 colorectal cancer cell 
lines with ciglitazone (at EC50 values) for up 
to 72 h and analysed for the PPARγ mRNA 
levels. Real-time PCR analysis demonstrated 
that the mRNA level was higher in HT-29 
compared to COLO 205 in both control and 
treated groups. Unexpectedly, the levels of 
mRNA were significantly reduced in 
ciglitazone-treated cell lines at all time points 
(Figure 2). A decrease in PPARγ transcripts 
was observed in both cell lines as early as 6 h 
of ciglitazone treatment and this reduced level 
was maintained for up to 72 h in both cell 
lines. 
 
 
Effects of ciglitazone on PPARγ protein 
levels in colon cancer cell lines 
Since ciglitazone activity downregulates 
PPARγ mRNA expression in the cell lines, it 
prompted us to determine whether this ligand 
has the same effect on PPARγ protein levels. 
For both HT-29 and COLO 205 (Figure 3), 
high PPARγ protein expression was detected 
in control groups at all time points. For HT-
29, a decreased in protein expression can be 
detected as early as 12 h. PPARγ protein level 
remained lower in treated cells. However, for 
COLO 205, the effect of ciglitazone was 
observed after 36 h where the protein level in 
treated cells decreased dramatically compared 
to untreated cells. PPARγ has a molecular 
weight of about 52 kD.  
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FIGURE 2 Ciglitazone effects on PPARγ1 mRNA 
expression in a) HT-29 and b) COLO 205 cell lines. 
Cells were treated with 20 µM (HT-29) or 30 µM 
(COLO 205) ciglitazone for 6-72 h. Gene expression was 
measured by quantitative real-time PCR. Data are 
expressed as mean ± sem (n=3). *p<0.01, significantly 
different from untreated control cells. 
a) 
b) 
FIGURE 1 Cytotoxic effect of ciglitazone in a) HT-
29 and b) COLO 205 cells. Cells were treated with 
ciglitazone (2.5-100 µM) or DMSO (control) for 0-72 
h. Cytotoxicity was measured based on LDH release  
by the cells. Data are given as mean ± standard error 
of mean (sem) (n=3). Significance was determined by 
conducting an independent Student T-test. *p<0.01 
were considered statistically significant (compared to 
control). 
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Induction of apoptosis by ciglitazone in 
human colorectal cancer cell lines 
The percentages of HT-29 and COLO 205 
cells undergoing apoptosis after 6-48 h of 
ciglitazone treatment were shown in Figure 4. 
For both cell lines, there was no significant 
difference in the percentage of apoptotic cells 
between untreated cultures and treated groups 
for up to 12 h of incubation. A remarkable 
increase in the number of apoptotic cells 
treated with ciglitazone was observed at 24 h 
onwards. At 48 h of treatment, about 64% of 
HT-29 and 43% of COLO 205 cells 
underwent apoptosis. The apoptotic effect was 
negligible in cells treated with DMSO at all 
incubation periods.   
 
 
 
 
 
Discussion 
Previous studies have reported the 
expression of PPARγ and the antitumour 
effects of its ligands in human malignancies 
(for review, refer to Koeffler, 2003). In the 
present study, we examined the expression of 
PPARγ and any antiproliferative effect of its 
synthetic ligand, ciglitazone, in human 
colorectal cancer cell lines. Real-time PCR 
and westen blot analyses have shown that 
PPARγ mRNA and protein levels were 
downregulated. The exact mechanism for this 
downregulation is unclear, however, our 
results are in agreement with a few previous 
studies.  
In 1999, Camp and colleagues demostrated 
that troglitazone reduced the PPARγ mRNA 
and protein levels as well as the DNA binding 
activity of PPARγ in 3T3-L1 fully 
FIGURE 4 Induction of apoptosis by ciglitazone 
in a) HT-29 and b) COLO 205 cells. Cells were 
treated with either DMSO as a control or 20 µM 
(HT-29) or 30 µM (COLO 205) ciglitazone for 0-
48 h. Cells were incubated with M30 
cytoDEATH antibody for CK18 detection. Data 
shown are the mean values ± s.e.m (n=3). 
Statistical analyses were performed using 
independent Student T-test. . *p<0.01 and 
**p<0.05 were considered statistically significant 
(compared to control). 
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FIGURE 3 Western blot analysis for PPARγ 
protein in a) HT-29 and b) COLO 205 cell lines. 
Cells were treated with 20 µM (HT-29) or 30 µM 
(COLO 205) ciglitazone for 12-72 h. Cell lysates 
electrophoresed on 10% sodium dodecyl sulfate-
polyacrylamide gel (100 µg/lane). Proteins from 
gels were transferred to nitrocellulose membrane, 
and PPARγ was detected with goat anti-human 
PPARγ polyclonal antibody and visualised with 
enhanced chemiluminescence. +C: positive control, 
C: control, T: ciglitazone-treated 
48h-C 48h-T 60h-C 60h-T 72h-C 72h-T
PPARγ 
PPARγ 
+C      0 h      12h-C  12h-T 24h-C 24h-T 36h-C 36h-T 
a) 
PPARγ 
    0h       12h-C 12h-T 24h-C  24h-T    36h-C    36h-T 
PPARγ 
  48h-C   48h-T  60h-C  60h-T  72h-C 72h-T 
b) 
The 4th Annual Seminar of National Science Fellowship 2004
129
differentiated adipocytes. BRL49653 (also 
known as rosiglitazone) reportedly has similar 
suppressive effect on PPARγ mRNA and 
protein levels in adipocytes (Rosenbaum and 
Greenberg, 1998). Perrey et al. (2001) also 
found that TZDs and the natural PPARγ 
ligand, 15d-PGJ2 acutely downregulated the 
expression of PPARγ mRNA in mature 
adipocytes. These three studies, however, did 
not clarify the exact mechanism underlying 
the downregulation of PPARγ, although 
Perrey et al. (2001) suggested that this was a 
phenomenon to protect the receptors from 
excessive consumption. In 2000, Hauser and 
colleagues reported that PPARγ protein levels 
were significantly reduced in adipose cells and 
fibroblasts in response to TZDs treatment. 
They suggested that degradation of PPARγ is 
correlated with the ability of the ligands to 
activate the receptor. Although ligand binding 
and activation of the activation function-2  
(AF2) domain induce the transcriptional 
function of PPARγ, these same processes also 
induce ubiquitination and subsequent 
degradation of the receptor by proteasome 
(Hauser et al., 2001).  
In this study, results have shown that 
although ciglitazone downregulated PPARγ 
mRNA and protein expression levels, the 
same ligand significantly inhibited growth and 
induced apoptosis in the cells. These results 
suggest that ciglitazone suppresses the growth 
of human colorectal cancer cells independent 
of PPARγ.  In 2001, Palakurthi and colleagues 
reported that the antiproliferative effect of 
TZDs is independent of PPARγ and mediated 
instead by the inhibition of translation 
initiation. This is due to activation of protein 
kinase R that phosphorylates the α subunit of 
eukaryotic initiation factor 2 (eIF2), thus 
rendering eIF2 inactive.  
A study by Nakashiro and colleagues 
(2003) have shown that troglitazone 
significantly supresses the growth of human 
oral squamous carcinoma (OCCC) cells, such 
as BHY cells, which do not express PPARγ 
mRNA and protein. Although troglitazone 
significantly suppressed the growth of OCCC 
cells, it did not induce activation of PPARγ 
(Nakashiro et al., 2003). Furthermore, a more 
recent study demonstrated that 2-cyano-3,12-
dioxoolean-1,9-dien-28-oic acid (CDDO), 
another ligand for PPARγ, had similar growth 
inhibitory activity in all cell lines expressing 
different levels of  PPARγ expression 
(Melichar et al., 2004). Moreover, the growth-
inhibitory activity of CDDO was unaffected 
by PPARγ antagonist T007 (Melichar et al., 
2004).  These results suggest that the growth-
inhibiting action of synthetic ligands may 
depend on some other mechanism without 
affecting PPARγ activation. Likewise, Li and 
colleagues (2001) demonstrated that 15d-PGJ2 
induced apoptosis in human myofibroblasts 
independently of PPARγ, since PPARγ is not 
expressed in these cells. According to their 
report, the receptor ligand caused rapid 
production of reactive oxygen species (ROS) 
while inducing apoptosis.  
In this study, although the mRNA 
expression level seems identical between both 
cell lines, HT-29 expresses higher level of 
PPARγ mRNA expression compared to 
COLO 205. This may be due to the fact that, 
HT-29 is more differentiated than COLO 205, 
since it originated from a well-differentiated 
adenocarcinoma, compared to COLO 205 cell 
line, which was established from a metastatic 
colonic adenocarcinoma. Sasaki et al., (2002) 
reported that there was a tendency towards 
higher levels of PPARγ expression levels with 
higher differentiated lung cancer.  
PPARγ has been shown to play an 
important role in regulating cell growth and 
death in various cancer cells. However, many 
factors contribute to the expression and 
regulation of PPARγ activity. Whether PPARγ 
has a direct role in cancer cell growth remains 
to be elucidated. The anticancer activity of 
TZDs which appear to be independent of the 
levels of PPARγ in cancer needs further 
evaluation.  
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